LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Subscribe To Our Newsletter & Stay Updated
